Biomarker Profile Corporation, USA
Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her Ph.D. dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis Systemic Lupus Erythematosis. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.
Biomarker discovery is a difficult series of experiments due to the number of different molecules in clinical samples, the wide dynamic range of these molecules, their fluctuations and modifications. Often, it is difficult to determine which molecules should be selected as biomarker candidates for a particular purpose. Biomarkers can be used as indicators of disease, disease progression, and response to therapy or complications. Often disease is studied in comparison to healthy controls. However, we find that the comparison of biomarkers across different disease yields a different set of candidates than if the disease were studied in isolation. In this talk, we will present our discovery strategy and discuss the development of a biomarker database to aid in biomarker selection.